At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 163 enrolled
Drug / intervention
Methylphenidate Transdermal Systemdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
In Brief
A Phase 3 clinical trial evaluating Methylphenidate Transdermal System for ADHD. Completed, enrolled 163 participants across 32 sites.
Detailed Summary
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartAug 2007
Primary CompletionFeb 2009
TodayJul 2026
First PostedJul 16, 2007
Enrollment StartAug 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.0 years ago
Interventions
Methylphenidate Transdermal Systemdrug
One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months